RECRUITING

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Description

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

Conditions

Atoptic Dermatitis
Talk to us

Related Conditions:

Atoptic Dermatitis

Study Overview

On this page

Study Details

Study overview

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Atopic Dermatitis

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

Condition
Atoptic Dermatitis
Intervention / Treatment

-

Contacts and Locations

Fremont

Center for Dermatology Clinical Research, Fremont, California, United States, 94538

Los Angeles

Metropolis Dermatology - Downtown Los Angeles, Los Angeles, California, United States, 90017

Pasadena

Skin and Beauty Center, Pasadena, California, United States, 91105

Boca Raton

Skin Care Research, LLC, Boca Raton, Florida, United States, 33486

Coral Gables

Driven Research, LLC, Coral Gables, Florida, United States, 33134

Hollywood

Skin Care Research - Hollywood Dermatology, Hollywood, Florida, United States, 33021

East Syracuse

Empire Dermatology, East Syracuse, New York, United States, 13057

Rochester

Skin Search of Rochester, Inc., Rochester, New York, United States, 14623

South Jordan

Jordan Valley Dermatology Center, South Jordan, Utah, United States, 84095

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Chronic AD that has been present for ≥6 months
  • * Validated-Investigator's Global Assessment score of ≥3
  • * EASI of ≥16
  • * BSA of AD involvement of ≥10%
  • * Any clinically significant abnormality in laboratory evaluations, physical examinations, vital signs, or ECG at Screening
  • * Use of certain medications
  • * Presence of skin comorbidities or other condition(s) that may interfere with study assessments
  • * Significant AD flare, in the opinion of the Investigator, within 4 weeks prior to study entry

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Evommune, Inc.,

Study Record Dates

2026-07